Hostname: page-component-7b7567c8c-p67k6 Total loading time: 0 Render date: 2026-11-19T16:04:05.741Z Has data issue: false hasContentIssue false

Plasma Exchange of Malignant Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

K.G. Warren*
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
P.A. Gordon
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
T.A. McPherson
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
*
9-101 Clinical Sciences Building, University of Alberta, Edmonton, Alberta, T6G 2B7.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

A 17-year old female with “malignant” multiple sclerosis died 45 weeks after the onset of the disease. Postmortem examination confirmed the clinical diagnosis of multiple sclerosis. After 30 weeks of rapid clinical progression, the patient was treated with two courses of plasma exchange therapy without immunosuppression. This form of therapy caused a drop in cerebrospinal fluid myelin basic protein levels in one instance, but not in another. Controlled clinical trials are required to determine whether plasma exchange therapy is of value in the management of patients with multiple sclerosis, and the monitoring of cerebrospinal fluid myelin basic protein, if elevated, may be one useful marker to follow as part of these studies.

Information

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1982